Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01253161
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:17.290004+00:00
Published At
2022-01-18T00:00:00+00:00
Record Updated At
2023-03-06
Results Posted At
2022-01-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Neuroendocrine Tumors", "Carcinoid Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-03-06"
protocolSection.identificationModule.nctId
"NCT01253161"
protocolSection.identificationModule.officialTitle
"Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-01-18"

Study condition terms

  • Neuroendocrine Tumors (protocolSection.conditionsModule.conditions)
  • Carcinoid Tumors (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.